| The Iodine Group | ||
|
Home | Orthoiodosupplementation | Body | Disease | Special | Overviews |
||
|
|
Upadhyay
Differential action of iodine on mitochondria from human tumoral- and extra-tumoral tissue in inducing the release of apoptogenic proteins.Upadhyay G, Singh R, Sharma R, Balapure AK, Godbole MM. Mitochondrion. 2002 Dec;2(3):199-210.
"Iodide is actively concentrated in the thyroid gland for thyroid hormone biosynthesis. Excess iodine has been observed to induce apoptosis in thyrocytes and mammary cells. The mechanism of iodine induced apoptosis is poorly understood. Among various cell organelles, mitochondria is known to provide conducive environment for the organification of iodine, i.e. iodination of different proteins. Mitochondria also play a central role in execution of apoptosis. To study the role of mitochondria in iodine induced apoptosis, we investigated the direct interaction of iodine and human breast mitochondria vis-a-vis its role in the initiation of apoptosis in vitro. We observed that mitochondria isolated from the tumor (TT) and extra-tumoral tissue (ET) of human breast display significant uptake of iodine. Mitochondrial proteins were observed to be predominantly iodinated in ET but not in TT mitochondria. Treatment with iodine showed an increase in mitochondrial permeability transition of TT and decrease in ET. Iodine induced released factor(s) other than cytochrome c from tumor mitochondria initiate(s) apoptosis in vitro, while those from ET mitochondria were non-apoptogenic in nature. To our knowledge, this is first report demonstrating that iodine acts differentially on mitochondria of tumor and extratumoral origin to release apoptogenic proteins from TT and has a protective effect on ET."
Functional expression of sodium iodide symporter (NIS) in human breast cancer tissue.Upadhyay G, Singh R, Agarwal G, Mishra SK, Pal L, Pradhan PK, Das BK, Godbole MM. Breast Cancer Res Treat. 2003 Jan;77(2):157-65.
"Sodium iodide
symporter (NIS) is a molecule involved in active accumulation of
iodine in thyroid gland for the biosynthesis of thyroid hormone.
Its expression has also been demonstrated in extra-thyroidal
tissues including lactating mice mammary gland and also in human
breast cancers. Iodide transport in thyroid cells through NIS is
the basis for using radioiodine for diagnosis and treatment of
differentiated thyroid carcinoma. The similar approach may prove
beneficial for the diagnosis and treatment of breast cancer if
iodine uptake, its retention and NIS expression can be shown
unequivocally in malignant tumors. The aim of the present study
was to investigate NIS expression, in vivo iodine transport
ability and fate of iodine in human breast tumors. Women (age
33-58 years) with infiltrating duct carcinoma confirmed by FNAC
and subsequent histopathology were the subject of this study.
Expression of NIS RNA and protein was confirmed by RNAase
protection assay, western blot and immunohistochemistry
respectively in surgically excised breast tumor tissue. Iodine
transport ability and its nature was assessed both in vivo and in
vitro. We report high NIS expression at both transcriptional and
translational level and its ability to transport iodine in human
breast tumors. The in vivo iodine transport ability was confirmed
by scintigraphy. Unlike thyroid, perchlorate and thiocyanate do
not inhibit iodine transport in breast tumors. The presence of
iodinated proteins suggests the longer retention time. The
unequivocal demonstration of NIS expression, its functionality
and retention of iodine by organification further provides
supportive evidence for use of radioiodine as an additional
treatment modality of human breast carcinoma." |
|
Home | Orthoiodosupplementation | Body | Disease | Special Topics | OverviewsThe Iodine Group | Books | Disclaimers | Contact Us | SearchCopyright: Zoe, 2006. |
||